These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37657262)

  • 1. Uncovering the dynamics of cellular responses induced by iron-carbohydrate complexes in human macrophages using quantitative proteomics and phosphoproteomics.
    Bossart J; Rippl A; Barton Alston AE; Flühmann B; Digigow R; Buljan M; Ayala-Nunez V; Wick P
    Biomed Pharmacother; 2023 Oct; 166():115404. PubMed ID: 37657262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of iron isomaltoside 1000/ferric derisomaltose versus iron sucrose in patients with chronic kidney disease: the FERWON-NEPHRO randomized, open-label, comparative trial.
    Bhandari S; Kalra PA; Berkowitz M; Belo D; Thomsen LL; Wolf M
    Nephrol Dial Transplant; 2021 Jan; 36(1):111-120. PubMed ID: 32049331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis.
    Shin HW; Go DY; Lee SW; Choi YJ; Ko EJ; You HS; Jang YK
    Medicine (Baltimore); 2021 May; 100(20):e24571. PubMed ID: 34011020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.
    Fell LH; Seiler-Mußler S; Sellier AB; Rotter B; Winter P; Sester M; Fliser D; Heine GH; Zawada AM
    Nephrol Dial Transplant; 2016 Nov; 31(11):1835-1845. PubMed ID: 27190361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A patient-level cost-effectiveness analysis of iron isomaltoside versus ferric carboxymaltose for the treatment of iron deficiency anemia in the United Kingdom.
    Pollock RF; Muduma G
    J Med Econ; 2020 Jul; 23(7):751-759. PubMed ID: 32208038
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous iron preparations transiently generate non-transferrin-bound iron from two proposed pathways.
    Garbowski MW; Bansal S; Porter JB; Mori C; Burckhardt S; Hider RC
    Haematologica; 2021 Nov; 106(11):2885-2896. PubMed ID: 33054113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency.
    Sindone A; Doehner W; Comin-Colet J
    ESC Heart Fail; 2023 Feb; 10(1):44-56. PubMed ID: 36178088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The cellular transformation of injected colloidal iron complexes into ferritin and hemosiderin in experimental animals; a study with the aid of electron microscopy.
    RICHTER GW
    J Exp Med; 1959 Feb; 109(2):197-216. PubMed ID: 13620849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron sucrose and ferric carboxymaltose: no correlation between physicochemical stability and biological activity.
    Praschberger M; Haider K; Cornelius C; Schitegg M; Sturm B; Goldenberg H; Scheiber-Mojdehkar B
    Biometals; 2015 Feb; 28(1):35-50. PubMed ID: 25326244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for the treatment of preoperative anemia in patients with menorrhagia: An open-label, multicenter, randomized study.
    Lee S; Ryu KJ; Lee ES; Lee KH; Lee JJ; Kim T
    J Obstet Gynaecol Res; 2019 Apr; 45(4):858-864. PubMed ID: 30932300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial.
    Jose A; Mahey R; Sharma JB; Bhatla N; Saxena R; Kalaivani M; Kriplani A
    BMC Pregnancy Childbirth; 2019 Feb; 19(1):54. PubMed ID: 30717690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience.
    Jesus-Silva JA; Lamplugh A; Dhada S; Burton JO; Bhandari S
    BMC Nephrol; 2020 Jun; 21(1):212. PubMed ID: 32493240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.
    Neiser S; Rentsch D; Dippon U; Kappler A; Weidler PG; Göttlicher J; Steininger R; Wilhelm M; Braitsch M; Funk F; Philipp E; Burckhardt S
    Biometals; 2015 Aug; 28(4):615-35. PubMed ID: 25801756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A; Bhandari S
    Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue biodistribution of intravenous iron-carbohydrate nanomedicines differs between preparations with varying physicochemical characteristics in an anemic rat model.
    Funk F; Weber K; Nyffenegger N; Fuchs JA; Barton A
    Eur J Pharm Biopharm; 2022 May; 174():56-76. PubMed ID: 35337966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a multifaceted intervention to promote the use of intravenous iron sucrose complex instead of ferric carboxymaltose in patients admitted for more than 24 h.
    Touchard J; Perrin G; Berdot S; Pouchot J; Loustalot MC; Sabatier B
    Eur J Clin Pharmacol; 2021 Feb; 77(2):189-195. PubMed ID: 32926203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Economic impact of ferric carboxymaltose in haemodialysis patients].
    Aiello A; Berto P; Conti P; Panichi V; Rosati A
    G Ital Nefrol; 2020 Aug; 37(Suppl 75):. PubMed ID: 32749086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and cost effectiveness of intravenous ferric carboxymaltose versus iron sucrose in adult patients with iron deficiency anaemia.
    Basha A; Ibrahim MIM; Hamad A; Chandra P; Omar NE; Abdullah MAJ; Aldapt MB; Hussein RM; Mahfouz A; Adel AA; Shwaylia HM; Ekeibed Y; AbuMousa R; Yassin MA
    PLoS One; 2021; 16(8):e0255104. PubMed ID: 34375369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.